NIH – Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

July 30, 2020 by dld5dt@virginia.edu

Purpose:

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.

Background:

National Institutes of Health (NIH) and other research funding organizations support numerous genomic and functional genomics studies that generate a large amount of genotype, phenotype, gene expression, and epigenetic data, which continue to be made available to the scientific community. Many of these datasets have not been analyzed to their full potential and further investigation will provide opportunities to answer important research questions at relatively low cost.

Several NCI programs support genomic and epidemiologic research to understand and clarify cancer risk, progression, and outcomes. These studies generate a wealth of individual- and population-level data, including molecular, lifestyle, clinical, and environmental data. Leveraging these various types of data through innovative data modeling and analysis allows new questions to be addressed and helps to advance the field of cancer research. NIH has made it a priority to make data more Findable, Accessible, Interoperable, and Reusable (FAIR) to researchers to further biomedical research, through several sharing policies, including the 2003 Data Sharing Policy, the 2015 Genomic Data Sharing (GDS) Policy, and the NCI Cancer Moonshot Public Access and Data Sharing Policy. NIH requirements for data sharing in grant applications, combined with public and private sector initiatives by donors, journals, and foundations, have led to unprecedented amounts of available data for secondary research. Publicly available molecular measurements have been successfully utilized to discover novel biomarkers of disease and to find novel uses for existing therapeutics.

The goal of this initiative is to address key scientific questions relevant to cancer genomics and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics, environmental, clinical, behavioral, lifestyle, and molecular profiles data, from various data sources whose number is expected to continue increasing as more data become available through data sharing.

Key Dates:

Open Date (Earliest Submission Date): September 05, 2020
Letter of Intent Due Date(s): Not Applicable
Application Due Date(s): Standard dates apply.

URL for more information:

https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html

Filed Under: Funding Opportunities